Amunix Pharmaceuticals, based in Mountain View, CA, is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. The company is leveraging its proprietary T cell engager (XPAT) and cytokine (XPAC) platforms to advance a pipeline of novel prodrugs that are selectively activated in the tumor microenvironment. Both platforms utilize Amunix's prodrug technology that has been clinically validated to extend drug half-life with limited immunogenicity. Amunix is advancing its lead development candidate, AMX-818, an XPAT T cell engager targeting HER2+ solid tumors, toward the clinic, and has several discovery programs underway, including an IL-12 XPAC program. By delivering breakthrough therapies that can safely harness the immune system, we aim to conquer cancer and save lives.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/05/20 | $73,000,000 | Series A |
Casdin Capital Delian Capital Frazier Healthcare Partners Longitude Capital Omega Funds  Polaris Partners Redmile Group Two River Venrock | undisclosed |
| 03/04/21 | $117,000,000 | Series B |
ArrowMark Partners Avidity Partners Bain Capital Life Sciences BlackRock CaaS Capital Management Casdin Capital Clough Capital Partners Franklin Templeton Janus Henderson Investors Redmile Group Venrock Viking Global Investors | undisclosed |
